|
DEVELOPMENT OF CHINA'S INDUSTRY
In 2008, the medical industry continued to keep fast growth, with the growth of total industrial output value basically equivalent to that from the same period of 2007. In sub-industries, the growth of the biological product industry is comparatively distinctive while that of traditional Chinese herbal sliced medicine processing industry and Chinese pharmaceutical industry slightly declined.
In 2008, the total industrial output value of the pharmaceutical industry accumulatively realized RMB790.387b, up by 25.16% year-on-year, with the growth falling by 0.29% from the same period of 2007. In the sub-industries, the industrial production of Chinese pharmaceutical industry and the chemical pharmaceutical industry rose by 23.26% and 223.94% year-on-year respectively, with the growth falling by 4.69% and 0.43% respectively from the same period of 2007. The traditional Chinese herbal sliced medicine processing industry grew quickly, with the total industrial output value rising by 32.1% year-on-year but falling by 5.22% from the same period of 2007. The traditional Chinese medicine manufacturing industry increased by 21.13% year-on-year, growing by 0.46% from the same period of 2007. The growth of the biological product industry was 30.32%, up by 7.67% from the same period of 2007.
The scale of the state-owned enterprises, corporate enterprises, privately-run enterprises and foreign-funded enterprises in the pharmaceuticals industry was relatively large. In 2008, the total industrial output value of the state-owned enterprises accumulatively increased by 15.38% year-on-year, with the growth falling by 7.92% from the same period of 2007; that of corporate enterprises accumulatively increased by 21.03% year-on-year, up by 1.27% from the same period of 2007; the privately-run enterprises developed rapidly, with the total industrial output value accumulatively increasing by 33.62% year-on-year, falling by 1.09% from the same period of 2007; the total industrial output value of foreign-funded enterprises rose by 23.38% year-on-year, with the growth falling by 0.51% from the same period of 2007.
In 2008, the nationwide output of medicinal chemicals accumulatively completed 2.2853 million tons, up by 0.85% year-on-year, with the growth falling by 15.02% from the same period of 2007 and the growth speed of output distinctively falling from the same period of 2007. In terms of the output of Chinese patent drug, in 2008 the output of Chinese patent drug completed 1.2726 million tons, up by 18.73% year-on-year, rising by 4.27% from the same period of 2007.
In 2008 the sales value of the pharmaceutical industry grew fast, slightly rising compared with 2007. In the sub-industries, the sales value of the chemical medicine dose industry and the biological product industry was distinctively raised compared with 2007. The sales value of the traditional Chinese herbal sliced medicine processing industry significantly fell.
In 2008, the sales value of the pharmaceutical industry accumulatively completed RMB751.14b, up by 26.03% year-on-year, with the growth speed rising by 1.42% from the same period of 2007. In the sub-industries, the sales value of the biological product industry increased by 31.53% year-on-year, with the growth speed rising by 9.17% from the same period of 2007. The sales value of the chemical medicine dose manufacturing industry rose by 3.37% from the same period of 2007. The sales value of the Traditional Chinese herbal sliced medicine processing industry increased rapidly, reaching 32.9%, falling by 7.2% from the same period of 2007. The sales value of the Chinese patent drug manufacturing industry rose by 0.85% compared with 2007.
In export, in 2008 the accumulative export delivery value of the pharmaceutical industry realized RMB72.324b, up by 13.75% year-on-year, with the growth falling by 6.76% from the same period of 2007. In the sub-industries, the export growth of the chemical medicine materials industry rose by 0.02% from the same period of 2007 while the export delivery value of the chemical medicine dose manufacturing industry fell by 8.53% year-on-year, with the decline distinctive. The export delivery value of the traditional Chinese herbal sliced medicine processing industry increased by 17.37% year-on-year, significantly falling by 34.56% from the same period of 2007. The export of the Chinese patent drug manufacturing industry distinctively dropped, with the growth of the accumulative export delivery value being 5.06%, falling by 12.47% from the same period of 2007, with the decline degree obvious. The growth of the export of the biological product industry stabilized.
In terms of import, in 2008 the import of pharmaceuticals accumulatively reached 66,753 tons, up by 43.8% year-on-year, rising by 26% from the same period of 2007; among them, import of bacteriophage declined by 14.1% year-on-year while the import of the bacteriophage preparation increased by 95.2% year-on-year, significantly rising by 88.3% compared with 2007.
In 2008, the accumulative investment of fixed assets in the pharmaceutical industry completed RMB106.191b, up by 25.9% year-on-year, with the growth significantly rising by 15.7% from the same period of 2007; the accumulative total industrial output value of large enterprises in the pharmaceutical industry increased by 22.61% year-on-year, up by 1.74% from the same period of 2007. The growth of the accumulative total industrial output value of medium-sized enterprises reached 19.11%, falling by 1.71% from the same period of 2007. The growth of the total industrial output value of small-sized enterprises was 32.21%, with a high growth speed, falling by 0.1% from the same period of 2007.
STATUS OF FOREIGN INVESTMENT
According to the statistics of MOFCOM, 139 foreign investment projects in Medicines industry(Medicines Industry (Code C27) hereinafter is in accordance with the National Economic Industrial Classification (GB/T4754-2202）.) were newly set up in 2009, 44 less than that of the same period in the last year, and the amount of the actual utilized foreign capital reached USD 944,860,000, up by 43.7％
year-on-year. The number of newly established foreign invested enterprises and the amount of the actual utilized foreign capital accounted for 0.59％and 1.05％
of the national total number or amount of foreign capital absorption in the Medicines industry during the same period.
According to the source of foreign capital, calculated by the amount of the actual utilized foreign capital, in 2009, countries or regions: Hong Kong, Denmark, Br. Virgin Is, United States, Bermuda ranked No.1 to No. 5 in the Medicines industry regarding the amount of FDI, accounting for 35.35%, 16.27%, 13.56%, 8.38%, 4.06% of the total amount of the actual utilized foreign capital of the industry separately.
In Medicines industry in 2009, ten Asian countries/regions (Hong Kong, Macau, Taiwan, Japan, Philippines, Thailand, Malaysia, Singapore, Indonesia and Korea) newly set up 89 enterprises in China, with the actual utilized foreign capital of USD 413,080,000, down by 19.09％
and up by 21.45％
separately year-on-year. The number of the newly established enterprises and the actual utilized foreign capital accounted for 64.03％
and 43.72％
of the national total number or amount of foreign capital absorption in the same period.
The US newly set up 26 enterprises in China, down by 35％
year-on-year; the actual utilized foreign capital reached USD 79,150,000, up by 0.7％
year-on-year. The number of the newly established enterprises and the amount of the actual utilized capital accounted for 18.71％
and 8.38％
of the national total number or amount of foreign capital absorption in the same period.
According to regional foreign capital absorption, 92 foreign-invested Medicines enterprises were newly set up in the Eastern area, with actual utilized foreign capital of USD 731,440,000, accounting for 66.19% and 77.41% of the national total number or amount of foreign capital absorption in the same period. In the Eastern area, Jiangsu, Tianjin and Guangdong Province ranked among the tops with respect to actual utilized foreign capital, had 33, 4 and 8 newly established foreign-invested enterprises separately, with the actual utilized foreign capital of USD 203,220,000, USD 197,650,000 and USD 99,500,000, accounting for 21.51%, 20.92% and 10.53% of the total amount of the actual utilized capital of the industry in the Eastern area separately.
38 foreign-invested Medicines enterprises were newly set up in the Central region, with actual utilized foreign capital of USD 136,970,000, accounting for 27.34% and 14.5% of the national total number or amount of foreign capital absorption in the same period. In the Central region, Jilin Province, Jiangxi Province and Hubei ranked among the tops with respect to actual utilized foreign capital, had 6, 4 and 7 newly established foreign-invested enterprises separately, with the actual utilized foreign capital of USD 80,610,000, USD 16,600,000 and USD 15,160,000, accounting for 8.53%, 1.76% and 1.6% of the total amount of the actual utilized capital of the industry in the Central region separately.
9 foreign-invested Medicines enterprises were newly set up in the Western area, with actual utilized foreign capital of USD 76,450,000, accounting for 6.47% and 8.09% of the national total number or amount of foreign capital absorption in the same period. Shaanxi Province, Guizhou Province and Guangxi Zhuang Autonomous Region ranked among the tops with respect to actual utilized foreign capital, with the actual utilized foreign capital of USD 19,830,000, USD 17,990,000 and USD 13,820,000, accounting for 2.1%, 1.9% and 1.46% of the total amount of the actual utilized capital of the industry in the Western area separately. Among them, Shaanxi Province and Guangxi Zhuang Autonomous Region had 1 and 2 newly established foreign-invested enterprises separately.
According to utilizing manners of the foreign capital, newly established projects of Medicines industry in 2009 are as follows : 55 Chinese-foreign equity joint venture projects, 78 wholly foreign-invested projects, 6 Chinese-foreign contractual joint venture projects. The amount of the actual utilized foreign capital reached USD 159,880,000、USD 739,270,000 and USD 25,230,000 separately．
|
